Project Grant R01CA300564
Award Date 5/1/26
Completion Date 4/30/31
Dollars Obligated $651K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Omaha, NE 68198, USA
Similar Awards
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of Nebraska Medical Center (UNMC) a Project Grant of $391,186 under the Cancer Treatment Research program (CFDA 93.395) effective September 1, 2025, with a completion date of August 31, 2027. This research project focuses on co-targeting insulin-like growth factor 1 receptor (IGF-1R) and glutaminase in Ewing sarcoma, a pediatric and young adult bone malignancy with poor survival outcomes once...
- Federal Grant Award Summary The National Cancer Institute awarded a $584,852 Project Grant to the University of Nebraska Medical Center (UNMC) under the Cancer Cause and Prevention Research program (CFDA 93.393) effective May 1, 2026 through April 30, 2031. This research initiative focuses on elucidating the mechanisms of genomic instability in DNA polymerase epsilon (POLE)-mutant tumors and identifying novel driver alleles that contribute to ultramutation phenotypes. The project will deliver...
- Federal Project Grant Award Summary The National Cancer Institute awarded $544,250 to the University of Nebraska Medical Center (UNMC) under the Cancer Treatment Research program (CFDA 93.395) for a five-year project running from August 4, 2025 through July 31, 2030. The award supports research investigating the immune drivers of persistent oncogenic human papillomavirus (HPV) infections in people living with HIV (PLWH), with an initial focus on oral HPV persistence as a precursor to...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $483,395 Project Grant under the Cancer Treatment Research program (CFDA 93.395) beginning September 1, 2025, and concluding August 31, 2027. This research initiative focuses on investigating P300 and CBP (Cyclic AMP-Response Element Binding Protein) as novel therapeutic targets in renal cell carcinoma (RCC), specifically clear cell RCC (ccRCC). The project will examine the therapeutic potential...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $482,236 to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) on August 1, 2025, with a project completion date of July 31, 2030. This investigator-initiated Phase 2 clinical trial will evaluate the safety and efficacy of combining trastuzumab deruxtecan (T-DXD), an antibody-drug conjugate, with the anti-EGFR (epidermal growth factor receptor)...
- Federal Project Grant Award Summary The National Cancer Institute awarded $730,398 to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) on April 1, 2026, with a completion date of March 31, 2031. This project grant supports research into the emergence of tumor regenerative states during neoadjuvant therapy in locally advanced rectal cancer (LARC). The research aims to determine whether resistance to total neoadjuvant therapy (TNT)—which...
- Federal Grant Award Summary The University of Cincinnati received a $162,000 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective July 1, 2025, through June 30, 2027. This award funds research to develop and evaluate novel combination treatment strategies targeting colorectal cancer patients with KRAS mutations. The project specifically investigates the efficacy of combining KRAS inhibitors with HER3 (human epidermal...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $730,398 to Sloan-Kettering Institute for Cancer Research through the Cancer Treatment Research program (CFDA 93.395) on September 1, 2025, for a five-year project period concluding August 31, 2030. This Project Grant supports research and development activities designed to advance novel treatment approaches for rectal cancer, with emphasis on organ preservation strategies that minimize patient morbidity. The...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Trustees of Columbia University in the City of New York a Project Grant totaling $682,673 under the Cancer Treatment Research program (CFDA 93.395) effective May 1, 2026, with completion targeted for April 30, 2031. This award funds research investigating the adaptation and evolution of resistance to pan-RAS inhibition in pancreatic ductal adenocarcinoma (PDAC), a disease responsible for over 52,000 annual deaths in...